AzTrials
AzTrials

Periodontal DiseasesPhase 4Antiox-SRPNCT06894667

The Effect of an Antioxidant Gel Compared to Chlorhexidine Gel During the Soft Tissue Healing Process: A Randomized Controlled Clinical Trial

A Phase 4 study testing Antioxidant gel and Antimicrobial gel in people with Periodontal Diseases, run by Kuwait University at 1 site in Kuwait.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This study aims to evaluate the comparative impact of chlorhexidine and antioxidant gel on postoperative biomarkers following SRP. By examining biomarkers related to inflammation, oxidative stress, and tissue healing, this research seeks to determine which treatment modality more effectively supports recovery and… Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Periodontal Diseases
What is being tested?
Antioxidant gel and Antimicrobial gel
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteKuwait
Study dates
1 Nov 2024to 1 Dec 2025
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Patients with Stage 3 or 4 periodontitis would be invited to participate in this study.
  • The following parameters will be used for the diagnosis of periodontitis: (a) presence of bleeding on gentle probing; (b)probing depth (PD) >6mm; and (c) marginal bone loss (MBL) of at least 3.

Who cannot join

  • Patients will be excluded from the study if they present with gingivitis alone, are currently using oral contraceptives, have systemic conditions such as diabetes or cancer, or are smokers (including those who quit within the past 6 months).
  • Recent antibiotic use within the last 3 months, NSAID or bisphosphonate use within the last 90 days, and any use of chlorhexidine in the past 6 months.

Trial locations and contacts

1 site in 1 country.

Kuwait1 site
  • Faculty of Dentistry

    Kuwait City, 13110

Other trials in Kuwait

About this study

Official title: The Effect of an Antioxidant Gel Compared to Chlorhexidine Gel During the Soft Tissue Healing Process Follow Scaling and Root Planing: A Randomized Controlled Clinical Trial

This study aims to evaluate the comparative impact of chlorhexidine and antioxidant gel on postoperative biomarkers following SRP. By examining biomarkers related to inflammation, oxidative stress, and tissue healing, this research seeks to determine which treatment modality more effectively supports recovery and reduces postoperative complications.

Understanding the differential effects of these interventions on postoperative biomarkers will contribute valuable insights into optimizing SRP outcomes. Correlations between biomarker levels and clinical outcomes, such as periodontal pocket depth and clinical attachment level changes will provide valuable information on the clinical relevance of the findings. This comparison will also guide clinicians in selecting the most appropriate postoperative care to enhance patient recovery and long-term periodontal health.

Read the detailed description

Background

Periodontitis is characterised by inflammation that results in the loss of periodontal attachment. Scaling and root planing (SRP) is a fundamental non-surgical treatment for periodontitis, which aims to remove the primary causative agents - dental plaque and calculus, from the tooth surfaces. Postoperative care is critical to ensure optimal healing and to manage potential inflammation and microbial load. Traditionally, chlorhexidine, an antimicrobial agent, has been utilized as an adjunctive treatment to prevent infection and manage inflammation following SRP. Chlorhexidine's broad-spectrum antimicrobial properties have been well-documented, and its application has been associated with reduced clinical symptoms and enhanced periodontal healing.

However, recent research has suggested potential benefits of antioxidant gels in promoting tissue repair and reducing oxidative stress, which could be beneficial in the postoperative period. Antioxidant gels, containing compounds such as vitamin C, vitamin E, or polyphenols, are proposed to mitigate oxidative damage and inflammation, potentially offering a different mechanism of action compared to traditional antimicrobial approaches.

Given these advances, there is a need to evaluate and compare the efficacy of chlorhexidine and antioxidant gels in managing postoperative outcomes following SRP. Specifically, assessing their impact on postoperative biomarkers, such as inflammatory cytokines, oxidative stress markers, and periodontal tissue regeneration indicators, could provide valuable insights into their relative effectiveness. In an animal model, found that animals treated with antioxidant gels healed faster and also led to an upregulation of TNFalpha and the antioxidant enzyme superoxide dismutase. However, to the best of our knowledge there are no human clinical studies that have established this relationship. Therefore, this study aims to compare the efficacy adjunctive treatment with chlorhexidine and antioxidant gels along with SRP in the management of patients with periodontitis.

Objectives The objectives of this study are to evaluate and compare the effects of chlorhexidine and antioxidant gel on inflammatory biomarkers (e.g.: Tumor Necrosis Factor-alpha (TNF-alpha); and antioxidant related markers (e.g.: Myeloperoxidase (MPO), among patients undergoing scaling and root planing (SRP). Additionally, the study aims to determine the clinical efficacy of these postoperative treatments in modulating the tissue response.

Methodology Ethics The present study will be performed following the guidelines of the Declaration of Helsinki as revised in 2013 for experimentation involving human patients. All volunteering individuals will be requested to read and sign a consent form written in simple Arabic and English and the study will be presented in accordance with the consolidation standards of reporting trails (CONSORT) guidelines. All participants will be informed that they can withdraw their participation at any phase of the study without consequence. Ethical approval will be obtained from Ethics Committee of Health Science Center at Kuwait University and Ministry of Health. Permission to recruit subjects for this study from the dental clinics of Jaber Hospital has been obtained from the Head of Clinics. The experimental protocol will be also registered at ClinicalTrial.gov.

Study Area/Setting

This prospective study will be conducted between March 2025 and June 2025 at the Dental Clinics of Jaber Hospital and at Kuwait University Dental Center. A convenient sample was selected from regular patients attending the dental clinics.

Grouping Periodontitis is a chronic multifactorial inflammatory disease associated with dysbiotic plaque biofilms and characterised by the progressive destruction of the tooth-supporting apparatus. The definition of periodontitis will be based on the consensus report of Workgroup-4 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. Patients with stage III and stage IV periodontitis will be included in this study. A total of 40 subjects would be divided into the following groups: Group-1: administration of chlorhexidine gel (n=20) and Group-2: administration of antioxidant gel (n=20).

The following parameters will be used for the diagnosis of periodontitis: (a) presence of bleeding on gentle probing; (b)probing depth (PD) >6mm; and (c) marginal bone loss (MBL) of at least 3. Patients will be excluded from the study if they present with gingivitis alone, are currently using oral contraceptives, have systemic conditions such as diabetes or cancer, or are smokers (including those who quit within the past 6 months). Additionally, exclusion criteria include recent antibiotic use within the last 3 months, NSAID or bisphosphonate use within the last 90 days, and any use of chlorhexidine in the past 6 months.

Questionnaire A standardized questionnaire will be used to gather information regarding age ( in years ), gender, medical, smoking, and oral health history, including the presence of systemic diseases ( Diabetes mellitus , hypertension ), smoking status, and any recent use of oral contraceptives, antibiotics, NSAIDs, bisphosphonates, or chlorhexidine. This will ensure accurate characterization of the study population and identification of any potential confounding factors. All participants will be asked about their daily tooth brushing habits and the date of the last dental visit and the procedure was done.

Clinical Procedure and Sample Collection All examiners involved in the clinical assessments, laboratory analysis, and statistical evaluations should ideally be blinded to avoid bias. At the initial baseline stage (T0), all participants will undergo non-surgical periodontal therapy, which entails plaque and calculus removal, the use of an ultrasonic scaler, and root planing with sterile curettes (Hu-Freiddy, Chicago, IL, USA). This procedure is expected to last about 60-90 minutes. After the non-surgical therapy, patients will be advised to follow routine oral hygiene practices. Participants will be divided into two groups: one group will receive chlorhexidine gel and the second group will be treated with an antioxidant gel (Tebodont®, Dr. Wild \& Co. AG, Basel). They will then be scheduled for a follow-up appointment 4 weeks later (T1).

Salivary Sample Collection The samples during T0 and T1 will be collected from the deepest pocket of the buccal side of the first or second molars as described in an earlier study.

Analysis of Salivary Biomarkers Samples will be stored at -80°C until ready for analysis. TNF-α and MPO will be analyzed using enzyme-linked immunosorbent assay (ELISA) kits from R\&D Systems (Minneapolis, MN, USA).

Clinical and Radiographic Examination For all participants, the Löe \& Silness gingival index (GI) and Silness \& Löe plaque index (PI), bleeding on probing (BOP), and periodontal pocket depth (PD) will be measured on the mesiobuccal, midbuccal, distobuccal, distolingual/palatal, mid-lingual/palatal, and mesio-lingual/palatal surfaces of all maxillary and mandibular teeth by trained and calibrated examiners.

Statistical Analysis Sample size was determined using a computer software G*-power (version 3.0.10; Franz Faul Universitat, Kiel, Germany) based on the values from a previous study 6. It was determined that a sample of 18 individuals/group will be required to get an 80% power and detect the difference in the TNF-α levels between the groups. The Kolmogorov Smirnov-test will be used to assess the data normality and appropriate bivariate and multivariable models will be employed to analyze the data. The level of significance will be set to p<0.05. All the analyses will be carried out using SPSS 27.0 (IBM Corp. Released 2017.IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp.).

Being tested
Antioxidant gel, Antimicrobial gel
Keywords
Antioxidant, Scaling and root planing
Medical subject headings
Periodontal Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Antioxidant gelDrug

    Also called Tea Tree oil (Tebodont®, Dr. Wild & Co. AG, Basel)

    An intraoral gel containing Tea Tree oil (Tebodont®, Dr. Wild \& Co. AG, Basel) would be applied to the gingival pockets after scaling and root planing

  • Antimicrobial gelDrug

    Also called Chlorhexidine gel (PERIOPLUS+ FORTE, Curaprox, Curaden)

    An intraoral gel containing 0.5% Chlorhexidine (PERIOPLUS+ FORTE, Curaprox, Curaden) would be applied to the gingival pockets after scaling and root planing

Study groups in NCT06894667
Study groupRoleWhat they receive
Control ArmActive comparatorA local gel containing 0.5% chlorhexidene (Curaprox Perioplus Focus Gel,PERIOPLUS+ FORTE, Curaprox, Curaden) would be administered
Receives: Drug: Antimicrobial gel
Test ArmExperimentalCommercially available antioxidant gel with Tea Tree oil (Tebodont®, Dr. Wild \& Co. AG, Basel) would be administered
Receives: Drug: Antioxidant gel

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Plaque Index

    to assess plaque accumulation

    Measured: baseline

  2. Plaque Index

    to assess plaque accumulation

    Measured: at 1 month post-intervention

  3. Gingival index

    for evaluating gingival inflammation

    Measured: baseline

  4. Gingival index

    for evaluating gingival inflammation

    Measured: at 1 month post-intervention

  5. Probing pocket depth (PPD)

    for measuring disease severity.PPD is measured in millimetres

    Measured: baseline

  6. Probing pocket depth (PPD)

    for measuring disease severity. PPD is measured in millimetres

    Measured: at 1 month post-intervention

  7. Clinical attachment level

    • Clinical attachment level (CAL) is calculated by adding or subtracting probing depth (PD) and gingival recession (GR). The formula is CAL = PD + GR. CAL is measured in millimeters.

    Measured: baseline

  8. Clinical attachment level

    Clinical attachment level (CAL) is calculated by adding or subtracting probing depth (PD) and gingival recession (GR). The formula is CAL = PD + GR. CAL is measured in millimeters.

    Measured: at 1 month post-intervention

  9. Bleeding on probing (BoP)

    to assess disease activity

    Measured: baseline

  10. Bleeding on probing (BoP)

    to assess disease activity

    Measured: at 1 month post-intervention

Secondary outcomes (4)
  1. TNF-α salivary levels

    TNF-α in micrograms will be analyzed using enzyme-linked immunosorbent assay (ELISA) kits from R\&D Systems (Minneapolis, MN, USA).

    Measured: baseline

  2. TNF-α salivary levels

    TNF-α in micrograms will be analyzed using enzyme-linked immunosorbent assay (ELISA) kits from R\&D Systems (Minneapolis, MN, USA).

    Measured: 1 month post intervention

  3. MPO salivary levels

    MPO in micrograms will be analyzed using enzyme-linked immunosorbent assay (ELISA) kits from R\&D Systems (Minneapolis, MN, USA).

    Measured: baseline

  4. MPO salivary levels

    MPO in micrograms will be analyzed using enzyme-linked immunosorbent assay (ELISA) kits from R\&D Systems (Minneapolis, MN, USA).

    Measured: 1 month post intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Mar 2025
  2. Study start1 Nov 2024
  3. Primary completion1 Sep 2025 (estimated)
  4. Study completion1 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
A total of 40 subjects would be divided into two groups: Group-1(Control): administration of chlorhexidine gel (n=20) and Group-2 (Test): administration of antioxidant gel (n=20).
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06894667
Sponsor's protocol ID
HSC_816
Acronym
Antiox-SRP
Status last verified
Mar 2025
First submitted
23 Feb 2025
Last updated
25 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: The data for the study will be maintained by the Principal investigator.

Publications

  • Sanz M, Herrera D, Kebschull M, Chapple I, Jepsen S, Beglundh T, Sculean A, Tonetti MS; EFP Workshop Participants and Methodological Consultants. Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline. J Clin Periodontol. 2020 Jul;47 Suppl 22(Suppl 22):4-60. doi: 10.1111/jcpe.13290.

    PubMed 32383274
  • Martin BJ, Campbell PM, Rees TD, Buschang PH. A randomized controlled trial evaluating antioxidant-essential oil gel as a treatment for gingivitis in orthodontic patients. Angle Orthod. 2016 May;86(3):407-12. doi: 10.2319/041515-251.1. Epub 2015 Aug 17.

    PubMed 26280662
  • San Miguel SM, Opperman LA, Allen EP, Svoboda KK. Use of antioxidants in oral healthcare. Compend Contin Educ Dent. 2011 Nov-Dec;32(9):E156-9.

    PubMed 23627309

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Antioxidant gel and Antimicrobial gel in people with Periodontal Diseases, run by Kuwait University at 1 site in Kuwait.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 25 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Kuwait. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Plaque Index (time frame: baseline). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06894667, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in